ClinicalTrials.gg
RecruitingNCT07096674Updated Apr 16, 2026

A Long-term Extension Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia

A Phase 2 interventional study of ORX750 and ORX750 in Narcolepsy Type 1, Narcolepsy Type 2 and Idiopathic Hypersomnia, sponsored by Centessa Pharmaceuticals (UK) Limited. Recruiting at 24 sites in 4 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-04-16.

Sponsored by Centessa Pharmaceuticals (UK) Limited (part of Eli Lilly and Company) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 30 studies in Idiopathic Hypersomnia with a site in United States — 12 open to participants now, 13 under way, 4 of them phase 3. Idiopathic Hypersomnia · United States.

Planned enrollment
16th of 27
90 · median 100
Started
2025
with 4 others
Phase 2
10 of 30
3 open now
Primary completion
2026-04
later than 0 of 12 live
Registered
26th of 30
by date
Lead sponsor
2 of 30
Centessa Pharmaceuticals (UK) Limited

Among the 30 studies in Idiopathic Hypersomnia with a site in United States, this one is the 16th largest by planned enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 26th registered.

Idiopathic Hypersomnia

53 studies on the registry are indexed under Idiopathic Hypersomnia; 24 are open to participants now.

Browse Idiopathic Hypersomnia studies →

Open to participants now

12 of the 30 studies in Idiopathic Hypersomnia with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Idiopathic Hypersomnia studies recruiting now, 4 (24%) set no upper age limit and 12 (71%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Idiopathic Hypersomnia with a site in United States, or all of them as a file.
02

Study summary

This study is a long-term extension (LTE) of the parent Study ORX750 0201, and will provide long-term open-label safety, tolerability, and efficacy of ORX750 in participants with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH).

03

Conditions studied

  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia

Keywords

  • NT1
  • NT2
  • IH
  • Narcolepsy
  • Narcolepsy Type 1
  • Narcolepsy Type 2
  • Idiopathic Hypersomnia
  • Excessive Daytime Sleepiness
  • Orexin Receptor 2 agonist
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of narcolepsy (NT1 or NT2) or IH who was eligible for and completed the full treatment period in the eligible parent study ORX750-0201 (CRYSTAL-1)
  • Is willing and able to adhere to additional protocol requirements

Exclusion criteria

Exclusion Criteria:

  • Development of any new disease/disorder that in the opinion of the investigator would make the participant unable to continue the study
  • Unable to refrain from excluded medications, including those used for treatment of narcolepsy or idiopathic hypersomnia
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Narcolepsy Type 1

    Narcolepsy Type 1 (Open Label)

    Drug: ORX750

  • Experimental
    Narcolepsy Type 2

    Narcolepsy Type 2 (Open Label)

    Drug: ORX750

  • Experimental
    Idiopathic Hypersomnia

    Idiopathic Hypersomnia (Open Label)

    Drug: ORX750

Interventions

  • DrugORX750

    Oral ORX750

  • DrugORX750

    Oral ORX750

  • DrugORX750

    Oral ORX750

06

What researchers measure

Primary outcomes

  1. Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs

    Time frame: Up to day 70

  2. Abnormal Laboratory Tests

    Number of Participants With Abnormal Changes From Baseline in Laboratory Tests

    Time frame: Up to day 70

  3. Abnormal Vital Signs

    Number of Participants With Abnormal Change From Baseline in Vital Signs

    Time frame: Up to day 70

  4. Abnormal ECG

    Number of Participants With Abnormal Change From Baseline in Electrocardiograms (ECG)

    Time frame: Up to day 70

  5. Suicidal Ideation or Behavior

    Number of Participants With Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)

    Time frame: Up to day 70

Secondary outcomes

  1. Cmax

    Cmax: Maximum Observed Plasma Concentration for ORX750

    Time frame: Up to day 63

  2. Tmax

    Tmax: Time of Maximum Concentration for ORX750

    Time frame: Up to day 63

  3. AUClast

    AUClast: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for ORX750

    Time frame: Up to day 63

  4. Cmax,ss

    Cmax,ss: Maximum Observed Concentration at Steady State for ORX750

    Time frame: Up to day 63

  5. AUCτ

    AUCτ: Area Under the Concentration-time Curve During a Dosing Interval at Steady State for ORX750

    Time frame: Up to day 63

  6. Maintenance of Wakefulness Test

    Change From Baseline in Mean sleep latency (average of the first 4 trials) in the Maintenance of Wakefulness Test (MWT)

    Time frame: Up to day 63

  7. Epworth Sleepiness Scale

    Change From Baseline in Epworth Sleepiness Scale (ESS)

    Time frame: Up to day 63

07

Study locations

24 of 24 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Apr 2026, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2025
First posted
Jul 31, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Apr 30, 2026
CompletionEst.
Apr 30, 2026
Last update
Apr 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07096674
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Aug 12, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
Apr 16, 2026

Study contacts

Orexin Centessa Program Lead
Contact
ORX750-LTE@centessa.com
617-468-5770

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion